Ephedra bronchodilator use likely to escape FDA prohibition -- NNFA counsel Young.
This article was originally published in The Tan Sheet
Executive Summary
EPHEDRA USE IN BRONCHODILATORS LIKELY WILL BE PERMITTED TO CONTINUE if FDA proceeds with regulatory action limiting use of the herb in dietary supplement products, Anthony Young, of the Washington, D.C. law firm Piper & Marbury, predicted in an Oct. 20 presentation at the Natural Products Expo East in Baltimore, Md. Young, who is general counsel to the National Nutritional Foods Association, participated in an Oct. 11 meeting on ephedra between FDA and a number of dietary supplement groups. The agency hopes to issue a proposal on ephedra by the end of the year.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: